Syon Capital LLC Invests $520,000 in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Syon Capital LLC acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 7,908 shares of the biotechnology company's stock, valued at approximately $520,000.

Other large investors have also modified their holdings of the company. Virtu Financial LLC bought a new stake in BioMarin Pharmaceutical during the third quarter valued at about $809,000. Tidal Investments LLC increased its position in BioMarin Pharmaceutical by 150.4% in the 3rd quarter. Tidal Investments LLC now owns 30,467 shares of the biotechnology company's stock worth $2,142,000 after buying an additional 18,300 shares during the period. Synovus Financial Corp boosted its position in shares of BioMarin Pharmaceutical by 25.7% in the third quarter. Synovus Financial Corp now owns 30,253 shares of the biotechnology company's stock valued at $2,127,000 after acquiring an additional 6,191 shares during the period. GAMMA Investing LLC grew its stake in shares of BioMarin Pharmaceutical by 57.5% in the fourth quarter. GAMMA Investing LLC now owns 1,232 shares of the biotechnology company's stock worth $81,000 after acquiring an additional 450 shares during the last quarter. Finally, Everence Capital Management Inc. acquired a new position in BioMarin Pharmaceutical during the 4th quarter valued at $333,000. 98.71% of the stock is owned by institutional investors.

Insider Activity

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,344 shares of the business's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $68.38, for a total transaction of $91,902.72. Following the completion of the sale, the chief accounting officer now directly owns 13,105 shares of the company's stock, valued at approximately $896,119.90. The trade was a 9.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.85% of the stock is currently owned by insiders.

BioMarin Pharmaceutical Price Performance

BMRN traded up $0.56 during midday trading on Friday, hitting $63.30. The company had a trading volume of 750,685 shares, compared to its average volume of 1,866,959. BioMarin Pharmaceutical Inc. has a twelve month low of $52.93 and a twelve month high of $94.85. The company has a market capitalization of $12.08 billion, a PE ratio of 28.77, a P/E/G ratio of 0.61 and a beta of 0.30. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33. The firm's 50-day simple moving average is $66.40 and its 200-day simple moving average is $65.97.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The firm had revenue of $747.31 million during the quarter, compared to analysts' expectations of $711.05 million. Equities research analysts predict that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on BMRN shares. Piper Sandler increased their target price on shares of BioMarin Pharmaceutical from $122.00 to $126.00 and gave the company an "overweight" rating in a research note on Thursday, February 20th. Royal Bank of Canada restated a "sector perform" rating and issued a $70.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Scotiabank boosted their price target on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a "sector perform" rating in a report on Thursday, February 20th. UBS Group raised their price objective on shares of BioMarin Pharmaceutical from $109.00 to $113.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Finally, Citigroup upped their target price on shares of BioMarin Pharmaceutical from $81.00 to $82.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. Seven investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, BioMarin Pharmaceutical currently has a consensus rating of "Moderate Buy" and an average price target of $93.14.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.